Finance
S&P 500 7,757.17 +44.60 +0.58% Dow 52,856.09 +360.19 +0.69% Nasdaq 26,702.86 +278.04 +1.05% NYSE Composite 24,253.12 +62.52 +0.26% Russell 2000 2,781.02 +7.60 +0.27% VIX 16.68 -0.63 -3.64%

APGE · Apogee Therapeutics, Inc.

NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD

Apogee Therapeutics Inc (APGE)

NASDAQ NMS - GLOBAL MARKET Biotechnology
Move probability → Options chain →
$135.09 +0.02 (+0.01%)
● At close: September 2 at 4:00:00 PM EDT
$135.08 -0.01 (-0.01%)
🌙 Overnight: 4:01:00 PM EDT
DAY'S RANGE $135.09
$135.06 $135.09
52-WEEK RANGE $135.09
$51.80 $135.09

What's happening

Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.

Key Statistics

Market Cap$10.22B
P/E (TTM1)—
EPS2 (TTM)$-4.34
Div Yield—
Beta3-1.06
Volume85,895
Open135.07
Prev Close135.07
Bid / Ask135.07 / 135.10
Next Earnings 2026-11-09

Analyst Recommendations

Strong buy 2 Buy 4 Hold 15 Sell 0 Strong sell 0

Aggregate ratings for 2026-10-01 (21 analysts polled by Finnhub) — consensus count.

Performance Overview (Trailing returns vs S&P 500 benchmark)

YTD RETURN
APGE +78.95%
vs S&P 500 +66.74%
6-MONTH RETURN
APGE +92.96%
3-MONTH RETURN
APGE +71.60%

Valuation Measures & Ratios

Enterprise Value4$10.12B
Forward P/E5—
PEG Ratio6-4.90
Price / Sales (TTM1)—
Price / Book78.35
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-29.88%
Return on Assets (ROA9)-28.08%
Avg Volume (3M)2,210,770
Glossary — what these abbreviations mean
1. TTM
Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
2. EPS
Earnings per share — net income divided by diluted shares outstanding.
3. Beta
A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
4. EV (Enterprise Value)
Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
5. Forward P/E
Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
6. PEG Ratio
P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
7. Price / Book
Share price divided by book value (assets minus liabilities) per share.
8. ROE
Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
9. ROA
Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
10. MRQ
Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
11. YoY
Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.

Short Interest

Shares Short4,203,052
Change from Prior Settlement-1.65%
% of Float—
Days to Cover (Short Ratio)3.47

Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-31. Reported bi-monthly with a reporting lag — not real-time.

Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.

Price history

Events

Drag horizontally to zoom into a section; use Reset view to restore all observations.

Technical signal summary

Calculating from the latest year of daily price history…

Calculating…
Show Technical Analysis Breakdown ▾ 10 Indicators

Not investment advice — read several signals together.

Indicators None active

Add lines over the price chart or a panel below it. Your choices are saved on this device.

Starter sets
Trend
Oscillators
Volume/volatility
Loading chart…

History limited by data provider; markers are heuristics, not signals.

Peer and sector context

No reviewed peer group is available for this symbol.

Balanced evidence

A deterministic summary of sourced facts—not an AI verdict.

Potential strengths

Not enough positive evidence under the current rules.

Potential concerns

Not enough cautionary evidence under the current rules.

Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.

No accessible free API for these — links go to the source directly.

Morningstar Motley Fool MarketBeat

Financials

No SEC EDGAR filer found for APGE (not a US GAAP filer, or not yet listed).

Institutional holders

SEC Form 13F filers holding APGE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.

Institutional ownership is not available for this symbol right now.

Insider activity

Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.

No SEC filer found for this symbol.

Recent SEC filings

Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.

Recent SEC filings are not available for this symbol right now.

Headlines about APGE (Apogee Therapeutics, Inc.). Links open the publisher — we don’t host full articles.

SEC filings ↓

← Back to the full dashboard · My watchlist